Alberto M.
- Country
- Spain
- Department
- Hematology Service
Research Overview
- Phase 3 Randomized Open-Label Study of Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Steroid-Refractory Acute Graft-Versus-Host Disease
- A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease
- Phase 3 Study of Ravulizumab in Thrombotic Microangiopathy Post-Hematopoietic Stem Cell Transplant in Adults and Adolescents
Data & Insights
Has run more than one trial at 116 of 168 partner sites.
Specializations
Graft-versus-Host Disease Management
The investigator specializes in treating acute and chronic graft-versus-host disease, with particular focus on innovative therapeutic approaches for both newly diagnosed and steroid-refractory cases.
- Steroid-refractory acute GVHD treatment
- Novel combination therapies for chronic GVHD
- High-risk GVHD interventions
Hematologic Malignancies
Expertise in treating B-cell lymphomas and related conditions, with emphasis on advanced cellular therapies and novel treatment approaches for refractory cases.
- Relapsed/refractory B-cell lymphoma management
- CAR-T cell therapy applications
- Innovative cellular therapeutics
Transplant Complications
Focus on managing and preventing complications associated with hematopoietic stem cell transplantation, including specialized treatments for post-transplant conditions.
- Transplant-associated thrombotic microangiopathy
- Microbiome-based therapeutic approaches
- Novel preventive strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.